Abstract:Background: Though infantile hemangioma (IH) is a common benign vascular tumor, its pathogenesis remains unclear. This study explored the function of hemangioma-derived stem cells (HemSCs) derived exosomes, which exerted an intercellular effect on hemangioma-derived endothelial cells (HemECs). Methods: First, HemSCs and HemECs were extracted and cultured. HemSCs derived exosomes (HemSCsexos) were harvested. miRNA sequencing and target prediction were used to explore differentially expressed miRNAs and potential binding targets. After HemECs were co-cultured with HemSCs-exos, a series of in vitro assays were then performed including cell counting kit-8 (CCK-8) assay, cell apoptosis assay, cell cycle assay and tube formation assay to evaluate proliferation, angiogenesis abilities, etc. qRT-PCR and Western blot were conducted to detect the expression level of target genes and proteins. Results: After co-culturing with HemSCs-exos, proliferation, and angiogenesis abilities of HemECs were enhanced, while apoptosis and cell cycle arrest rate were decreased. MiR-196b-5p was observed to be significantly highly expressed in HemSCs-exos. CDKN1B was identified as the binding target of miR-196b5p. HemECs' proliferation and angiogenesis abilities were elevated when co-cultured with exosomes from HemSCs transfected with miR-196b-5p mimic. In addition, apoptosis rate declined, and lower cells were arrested in G0/G1 phases. Cyclin E, bcl-2 were significantly highly expressed, whereas p27, Bax expression were significantly down-regulated. The positive effect of miR-196b-5p in HemSCs-exos was dramatically reversed when HemECs were transfected with oe-CDKN1B. Conclusions: The current study found a novel intercellular interaction between IH cells. Briefly, exosomederived miRNA-196b-5p in HemSCs could facilitate proliferation and angiogenesis abilities, and attenuate apoptosis and cell cycle repression rate of HemECs by directly binding with CDKN1B.

Characterization of epigenetic and transcriptional landscape in infantile hemangiomas with ATAC-seq and RNA-seq

Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway

Computer and Statistical Analysis of Transcription Factor Binding and Chromatin Modifications by ChIP-seq Data in Embryonic Stem Cell

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation

Transcriptional data analysis reveals the association between infantile hemangiomas and venous malformations

Non-coding RNA in infantile hemangioma

Expression profile of circular RNAs in infantile hemangioma detected by RNA-Seq.

A novel hsa_circ_0006903 circular RNA promotes tumor development and dendritic cells activated expression in infantile hemangioma

Cell Fate Regulation During the Development of Infantile Hemangioma

Identifying Potential Diagnostic and Therapeutic Targets for Infantile Hemangioma Using WGCNA and Machine Learning Algorithms

Integrated WGCNA and PPI Network to Screen Hub Genes Signatures for Infantile Hemangioma

Differentiation and Pro-Angiogenic Potential of Infantile Hemangioma Stem Cells

Transcriptional Regulatory Network Controlling the Ontogeny of Hematopoietic Stem Cells

868 Hypoxia Induced Cyr61 Productions Involved in the Pathogenesis of Infantile Hemangioma

Silencing long non‑coding RNA NEAT1 suppresses the tumorigenesis of infantile hemangioma by competitively binding miR‑33a‑5p to stimulate HIF1α/NF‑κB pathway

Exosome-derived Mir-196B-5p Facilitates Intercellular Interaction in Infantile Hemangioma Via Down-Regulating CDKN1B

CENPF May Act as a Novel Marker and Highlight the Influence of Pericyte in Infantile Hemangioma

ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis

The role of multipotential stem cells in human infantile hemangioma

ALKBH5 facilitates the progression of infantile hemangioma by increasing FOXF1 expression in a m6A-YTHDF2 dependent manner to activate HK-2 signaling

2010 - IDENTIFYING NECESSARY CHROMATIN STATES AND TARGETS FOR HEMOGENIC SPECIFICATION AND REPROGRAMMING